New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting
Press release – Oslo, Norway, December 5th, 2022: Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at the 22[nd] Annual Society of Urologic Oncology (SUO) Meeting demonstrating that Blue Light Cystoscopy (BLC[®]) decreases the risk and prolongs time to recurrence based on Real World Evidence from the U.S. multi-institutional Blue Light Cystoscopy with Cysview[®] Registry database.This large, prospective, longitudinal, multisite registry collects data on NMIBC* patients who have undergone transurethral resection of bladder tumor (TURBT) using Blue Light as